NIH #1R41CA071118-01
HEMOGLOBIN ALLOSTERIC MODIFIERS--NOVEL ANTITUMOR METAS
- Amount
- $77K
- Period
- 1996-09-24 → 1997-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at ALLOS THERAPEUTICS, INC.
Cancer, Hypoxia, and Metabolism · Cancer Research
14 total · 0 active
NIH #1R41CA071118-01
Awarded at ALLOS THERAPEUTICS, INC.
NIH #5R01CA050174-05
Awarded at DANA-FARBER CANCER INST
NIH #5R01CA050174-04
Awarded at DANA-FARBER CANCER INST
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
Supplementary Figure S3 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Supplementary Figure S8 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Supplementary Figure S9 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Figure S2 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Supplementary Figure S7 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Supplementary Table S2 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Supplementary Figure S4 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Supplementary Figure S10 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Supplementary Figure S5 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Supplementary Table S1 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Figure S1 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Supplementary Figure S6 from HTS384 NCI60: The Next Phase of the NCI60 Screen
2026-06-17
Cancer Research · 2026-04-03
Neuro-Oncology · 2025-11-01
Proceedings of the National Academy of Sciences · 2025-10-23 · 3 citations
Molecular Cancer Therapeutics · 2025-10-22
Molecular Cancer Therapeutics · 2025-10-22
2025-10-08
2025-10-08
2025-10-08